Findings

What do systematic reviews say?

7 questions · 9 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 22.2%GRADE not reported 0 · 0%Very low 2 · 22.2%Low 1 · 11.1%Moderate 4 · 44.4%High 0 · 0%

Low molecular weight heparin vs active control

Major bleeding · ambulatory cancer patients receiving chemotherapy

The review found no eligible studies for this question.

3 findings from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 0.14 [0.01, 2.76]
2 studies · 781 participants
Low
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low molecular weight heparin vs no thromboprophylaxis

Major bleeding · ambulatory cancer patients receiving chemotherapy

Low‐molecular‐weight heparin probably leads to higher major bleeding compared with no thromboprophylaxis (moderate certainty).

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 1.63 [1.12, 2.35]
15 studies · 7282 participants
Moderate

Low molecular weight heparin vs no prophylaxis

Major bleeding · adults undergoing KA

Low‐molecular‐weight heparin showed no clear difference in major bleeding ( compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
RR 0.98 [0.06, 15.72]
1 study · 1451 participants
Moderate

Ultra‐low‐molecular‐weight heparin vs placebo

Major bleeding · ambulatory cancer patients receiving chemotherapy

Ultra‐low‐molecular‐weight heparin showed no clear difference in major bleeding compared with placebo (moderate certainty).

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 1.05 [0.55, 2]
1 study · 3172 participants
Moderate

Low molecular weight heparin vs vitamin K antagonist (VKA)

Major bleeding · people with cancer with thrombosis prophylaxis and central venous catheters

It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes major bleeding (up to 3 months) compared with vitamin K antagonist (VKA) (very low certainty).

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
RR 3.11 [0.13, 73.11]
2 studies · 289 participants
Very low

Low molecular weight heparin vs no LMWH

Major bleeding · people with cancer with thrombosis prophylaxis and central venous catheters

It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes major bleeding (up to 3 months) compared with no LMWH (very low certainty).

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
RR 1.49 [0.06, 36.28]
4 studies · 1018 participants
Very low

Low molecular weight heparin vs no prophylaxis

All adverse effects, including allergies at injection site, minor and major bleeding, others ( · adults undergoing KA

Low‐molecular‐weight heparin showed no clear difference in all adverse effects, including allergies at injection site, minor… compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
RR 1.85 [0.95, 3.59]
5 studies · 1978 participants
Moderate